Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 10/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116469 | 1.00 | MAPT (0.48) | MAPTMEN1KMT2ANPC1GAA | |
| SCHEMBL2116471 | 1.00 | MAPT (0.48) | MAPTMEN1KMT2ANPC1GAA | |
| SCHEMBL2116467 | 1.00 | MAPT (0.48) | MAPTMEN1KMT2ANPC1GAA | |
| SCHEMBL456730 | 0.89 | MAPT (0.37) | MAPTMEN1KMT2ANPC1GAA | |
| SCHEMBL716922 | 0.89 | MAPT (0.37) | MAPTMEN1KMT2ANPC1GAA | |
| SCHEMBL716923 | 0.89 | MAPT (0.37) | MAPTMEN1KMT2ANPC1GAA | |
| SCHEMBL716924 | 0.89 | MAPT (0.37) | MAPTMEN1KMT2ANPC1GAA | |
| SCHEMBL19331536 | 0.88 | MAPT (0.36) | MAPTMEN1KMT2ANPC1GAA | |
| SCHEMBL19331535 | 0.88 | MAPT (0.36) | MAPTMEN1KMT2ANPC1GAA | |
| SCHEMBL715580 | 0.86 | MAPT (0.36) | MAPTMEN1KMT2ANPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396315-B1 | QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-08-31 | — | — | EP | disclosed |
| EP-2403847-B1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-03-02 | — | — | EP | disclosed |
| US-8785628-B2 | Triazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2014-07-22 | — | — | US | disclosed |
| US-8513284-B2 | Fused pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-8399483-B2 | Quinoxaline and quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2012-03-01 | — | — | US | disclosed |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA, S.A. (BE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | MAP3K15, PI4KA, MAP3K20 | MAPT 1229/4885MEN1 3000/4885KMT2A 1670/4885 |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | MAPT 1748/4885MEN1 3086/4885KMT2A 2560/4885 |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | MAPT 1441/4885MEN1 3999/4885KMT2A 4018/4885 |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | PDXK, PDPK1, PIKFYVE | MAPT 2318/4885MEN1 1813/4885KMT2A 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.